Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer
Notified -
Globe Newswire8-10-2025, 18:09
Calm Your Financial Fears: Beginner’s Guide To Investing In 8-02-2023, 02:37